Literature DB >> 22684556

Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry.

Shiwu Wu1, Lan Yu1, Zenong Cheng1, Wenqing Song1, Lei Zhou1, Yisheng Tao2.   

Abstract

Maspin belongs to the serine protease inhibitor (serpin) family and has been proven to be a suppressor of tumor growth and metastasis in many types of tumors. The purpose of this study was to investigate the expression of maspin in non-small cell lung cancer (NSCLC) and its relationship to vasculogenic mimicry (VM). A total of 160 specimens of NSCLC were involved in this study and 20 specimens of normal lung tissue served as controls. VM, microvessel density (MVD) and the expression of maspin were detected by using immunohistochemical staining. The results showed that the positive rates of maspin and VM in the NSCLC group were 48.1% (77/160) and 36.9% (59/160), respectively, which were significantly different from those in the control group with the positive rates of maspin and VM being 100% and 0% respectively (P<0.05). VM, MVD and the expression level of maspin were significantly related to tumor differentiation, lymph node metastasis, clinical stages and postoperative survival time (all P<0.05). The maspin expression in patients with squamous cell carcinoma was significantly higher than that in those with adenocarcinoma (P<0.05). The maspin expression was negatively correlated with VM and MVD, and there was a positive correlation between VM and MVD. Maspin-negative expression, VM and high MVD score were negatively related to the 5-year-survival rate. PTNM stages, VM, MVD and maspin expression were independent prognostic factors for NSCLC (P<0.05). It was suggested that the loss of expression of maspin may participate in the invasion and metastasis of NSCLC and it has a positive relationship to VM in NSCLC. Combined detection of maspin, VM and MVD may help predict the progression and prognosis of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684556     DOI: 10.1007/s11596-012-0060-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  40 in total

1.  Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital.

Authors:  Tokimasa Kumada; Koichi Tsuneyama; Hideki Hatta; Shin Ishizawa; Yasuo Takano
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

Review 2.  The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.

Authors:  Fulvio Lonardo; Xiaohua Li; Alexander Kaplun; Ayman Soubani; Seema Sethi; Shirish Gadgeel; Shijie Sheng
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 3.  A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge.

Authors:  Shijie Sheng
Journal:  J Cell Physiol       Date:  2006-12       Impact factor: 6.384

4.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

5.  Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma.

Authors:  Wei Wang; Peng Lin; Chunrong Han; Wenjuan Cai; Xiulan Zhao; Baocun Sun
Journal:  J Exp Clin Cancer Res       Date:  2010-06-02

6.  Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma.

Authors:  Masanao Nakashima; Nobuyuki Ohike; Koichi Nagasaki; Mitsuru Adachi; Toshio Morohoshi
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-12       Impact factor: 4.553

7.  Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells.

Authors:  Valerie A Odero-Marah; Zhila Khalkhali-Ellis; Jirapat Chunthapong; Sumaira Amir; Richard E B Seftor; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

8.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

9.  Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas.

Authors:  Baocun Sun; Shiwu Zhang; Xiulan Zhao; Wei Zhang; Xishan Hao
Journal:  Int J Oncol       Date:  2004-12       Impact factor: 5.650

10.  Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins.

Authors:  Weiguo Zhang; Heidi Y Shi; Ming Zhang
Journal:  BMC Cancer       Date:  2005-05-20       Impact factor: 4.430

View more
  13 in total

Review 1.  Advanced research on vasculogenic mimicry in cancer.

Authors:  Lili Qiao; Ning Liang; Jiandong Zhang; Jian Xie; Fengjun Liu; Deguo Xu; Xinshuang Yu; Yuan Tian
Journal:  J Cell Mol Med       Date:  2015-01-19       Impact factor: 5.310

2.  A bladder cancer microenvironment simulation system based on a microfluidic co-culture model.

Authors:  Peng-fei Liu; Yan-wei Cao; Shu-dong Zhang; Yang Zhao; Xiao-guang Liu; Hao-qing Shi; Ke-yao Hu; Guan-qun Zhu; Bo Ma; Hai-tao Niu
Journal:  Oncotarget       Date:  2015-11-10

3.  Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.

Authors:  Feng Zhang; Chun-Mei Zhang; Shu Li; Kun-Kun Wang; Bin-Bin Guo; Yao Fu; Lu-Yang Liu; Yu Zhang; Hai-Yu Jiang; Chang-Jun Wu
Journal:  Mol Med Rep       Date:  2017-11-14       Impact factor: 2.952

4.  HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter.

Authors:  Jian Yang; Dong-Ming Zhu; Xiao-Gang Zhou; Ni Yin; Yi Zhang; Zi-Xiang Zhang; De-Chun Li; Jian Zhou
Journal:  Oncotarget       Date:  2017-07-18

5.  Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in patients with breast cancer.

Authors:  Yanwei Shen; Jianfeng Quan; Mengying Wang; Shuting Li; Jiao Yang; Meng Lv; Zheling Chen; Lingxiao Zhang; Xiaoai Zhao; Jin Yang
Journal:  Oncotarget       Date:  2017-04-07

6.  MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression.

Authors:  Wenming Liu; Chunping Lv; Bin Zhang; Quansheng Zhou; Zhifei Cao
Journal:  RNA       Date:  2017-04-10       Impact factor: 4.942

Review 7.  Overview of advances in vasculogenic mimicry - a potential target for tumor therapy.

Authors:  Hong Ge; Hui Luo
Journal:  Cancer Manag Res       Date:  2018-08-02       Impact factor: 3.989

8.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

9.  Integrin β1 is an essential factor in vasculogenic mimicry of human cancer cells.

Authors:  Ryota Kawahara; Yuki Niwa; Siro Simizu
Journal:  Cancer Sci       Date:  2018-07-09       Impact factor: 6.716

10.  Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.

Authors:  Aparna Maiti; Qianya Qi; Xuan Peng; Li Yan; Kazuaki Takabe; Nitai C Hait
Journal:  Int J Oncol       Date:  2019-05-06       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.